Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
  • A61F9/007—Methods or devices for eye surgery
  • A61F9/00772—Apparatus for restoration of tear ducts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/28—Materials for coating prostheses
  • A61L27/30—Inorganic materials
  • A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/28—Materials for coating prostheses
  • A61L27/30—Inorganic materials
  • A61L27/32—Phosphorus-containing materials, e.g. apatite
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
  • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
  • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2430/00—Materials or treatment for tissue regeneration
  • A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus

Definitions

• the present invention relates to a device for producing an artificial trough duct on the human or animal body, as well as an operating set with the corresponding components for
• the anatomical structures of the lacrimal apparatus are referred to, as a derivative of the lacrimal ducts formed
• Tear channels comes, so z. B. by a Tränenwegssondtechnik and lacrimal lavage with a tear duct cannula the lacrimal ducts are examined for permeability. However, the bony part of the tear ducts can not be easily examined in this way in a patient. If problems occur in the area of the tear ducts or bags, such as a partial or perfect blockage (called constriction or stenosis), so may in the context of
• a silicone or silastic loop are formed, which leads from the nose through one of the two tear ducts and is guided in the eye's area through the other tear duct back into the nose.
• the two ends of the silicone or Silastikschlinge be knotted.
• This loop remains in the tear ducts for between 3 and 12 months before being removed.
• This procedure is called U-intubation or ring intubation.
• This form of intubation serves as a kind of splint or stabilization of the local situation.
• the tear ducts are blocked again after scarring is removed from the ring intubation. Partially comes in a short-stretched stenosis a
• Balloon dilatation is used.
• lasers and microdrills are sometimes used to overcome punctate stenosis of the tear ducts (canaliculi).
• postoperative U intubation is necessary, as described.
• Partial silicone bands are used for temporary splinting to support deformed tissue.
• the mentioned silicone splint is removed again after about 3 and 12 months, which requires further intervention.
• the mentioned micro drill can be driven either by a motor, by compressed air or hydraulically. It can also be a microdrill that is manually driven.
• the microdrill preferably has a drill bit (preferably a twist drill) that is so thin and long that it passes through a hollow (guide) probe the right position in the body can be performed.
• the diameter of the drill bit is preferably between 0.5 mm and 0.8 mm.
• the mentioned microdrill may be part of the scope of the operation set. The use of such a silicone splint is not recommended for the normal case, since so far no high success rates can be achieved.
• either a rotationally symmetrical hollow body or a rotationally symmetrical solid body is used as the implant.
• the corresponding body is at all
• Embodiments made of resorbable material ie.
• the body decomposes after a given time. Until then, the structures on the human or animal body have stabilized locally and permanently. Therefore, it is advantageous if the implant degrades slowly so as to give way to the newly grown, natural structures.
• FIG. Figure 1 shows a schematic illustration of a human eye and part of the nose
• FIG. 2A shows a schematic perspective view (not to scale) of a hollow body serving as an implant according to the invention
• FIG. 2B shows a schematic cross section (not to scale) of the
• FIG. 3A shows a schematic longitudinal section (not to scale)
• an eye-side end piece of a further implant which has a funnel-shaped enlargement
• FIG. 3B shows a schematic cross-section (not to scale) of the funnel-shaped extension of the implant according to FIG. 3A;
• FIG. 4 shows a schematic longitudinal section (not to scale)
• a nose-side end piece of a further implant which has a cutting edge
• FIG. 5 shows a schematic side view of a probing needle
• FIG. Fig. 6 shows a schematic illustration of a human eye and a part of the nose with an implanted implant according to the invention
• FIG. 7 shows a schematic illustration of a human eye and a part of the nose with an implant implanted by means of a probing needle according to the invention
• FIG. Fig. 8 shows a schematic illustration of a human eye and a part of the nose with an implanted implant according to the invention
• FIG. 9 shows a schematic illustration of a human eye and a part of the nose with two implanted implants according to the invention
• FIG. 10A shows a schematic side view of a guide needle or
• FIG. 10B shows a schematic side view of the sliding of the
• FIG. IOC is a schematic side view of the implant on the guide needle or probe of Fig. 10A in its final position;
• FIG. 11 shows a schematic side view of a combination of a
• FIG. 12A shows a schematic side view (not to scale) of an eye-side end piece of a further implant, according to the invention, which has a widening extension;
• FIG. 12B shows a schematic longitudinal section (not to scale) of an eye-side end piece of a further implant, according to the invention, which has a widening extension;
• FIG. 13 shows a schematic side view (not to scale) of an eye-side end piece of a further implant, according to the invention, which has a cylindrical construction with a
• FIG. 14 is a schematic side view of a solid body serving as an implant, wherein the solid body during the
• Implanting is connected to a guide needle or probe
• FIG. 15A shows in a highly schematic sectional view a newly created tear duct in which a full implant is seated
• FIG. 15B shows in a highly schematic sectional view the
• FIG. 16A shows a schematic side view of a section of a
• FIG. 16B shows a highly schematic sectional view of an implant according to FIG. 16A, which is designed as a full implant;
• FIG. FIG. 16C shows a highly schematic sectional view of an implant according to FIG. 16A, which is designed as a cylindrical implant.
• tear ducts used for tear ducts, tear ducts or tear tubes.
• these are the so-called dissipative tear ducts 2, 3, which lead from the eye 1 into the inside of the nose, as shown in FIG. 1 indicated.
• the lower turbinate 8 is a skull bone, which is the bony basis of the same nasal concha.
• the lower turbinate 8 runs along the lateral nasal wall 12. It consists of a cancellous bone lamella, which is partially rolled up like a leaf around its longitudinal axis.
• the lateral nasal wall 12 is composed of parts of the upper jaw, the tear bone, the palatine bone and the sphenoid bone. It carries the conchae nasales (nasal turbinates), of which the upper turbinate 10 and the middle turbinate 9 belong to the ethmoid bone and the lower turbinate 8 forms an independent bone.
• the nasal concha 8, 9, 10 are created as pairs and are separated by the so-called septum.
• the septum (nasal septum 12) is divided into a cartilaginous and a bony part.
• Cartilago septi nasi together with the lateral cartilage of the outer nose, unites and contributes to the stability of the nose.
• Part of the septum consists of parts of maxiila (front
• Nasal turbinates 10 and 9 belong to the ethmoid bone, while the lower nasal turbinates have 8 distinct bones as mentioned.
• nasal septum 12 nasal septum
• right and left nasal cavities 11 In the figures, only the left nasal main cavity 11 is shown.
• the implants 100 of the invention can be easily and safely created a drainage of the tear fluid.
• the implant 100 can be inserted from the "dangerous" area into the less dangerous area, ie the implant 100 is pushed from the eye 1, for example, into the lower tear duct 3, so that the end 101 of the implant 100 in the area of the tear-gas duct 7 or in the area of one of the nasal turbinas 8 or 9.
• the implant 100 preferably comprises PE (polyethylene), PU (polyurethane) plastic or polyglycolamide derivative in all embodiments that are non-absorbable and that either remain permanently in the body or are later removed.
• the cylindrical or tubular body of the implant 100 is preferably 100% of PE (polyethylene) or PU in all embodiments
• Polyurethane or polyglycolamide derivative plastic or bioceramics, preferably calcium phosphate ceramic manufactured.
• hollow cylindrical implant 100 is preferably 0.5 to 0.8 mm and the outer diameter of the implant 100 may be up to 1.5 mm.
• An exemplary hollow cylindrical implant 100 is shown in FIG. 16C shown in section. Preferably, an outer diameter of about 0.8 mm.
• Wall thickness D of the rotationally symmetrical, hollow cylindrical implant 100 is preferably between 0.15 mm and 0.5 mm.
• the total length L of the implant 100 is preferably between 1 and 4 cm and the implant 100 is severed or cut as needed after insertion.
• the hollow cylindrical implants 100 can at all
• Embodiments are relatively stiff (in which case they have a certain flexibility).
• a rotationally symmetrical, hollow cylindrical implant 100 a rotationally symmetrical, cylindrical solid body can also serve as an implant 100, see FIG. 16B.
• the outer diameter of the solid 100 serving as an implant can be up to 1 mm. Preferred is a
• Implant 100 is preferably between 1 and 10 cm and the
• Implant 100 is severed or cut as needed after insertion.
• the solid body may be rigid in all embodiments (in which case it has a certain bendability), or it may be flexible in itself.
• the procedure starts from the tear point 5 or 6. Preferably, it will be buggy first.
• Either a Bugiernadel or - probe (a Bugiernadel or probe 201 serves the widening or
• Expanding or a probing needle 200 (see Fig. 5 and 7) is used to from the tear point 5 or 6 through the tear duct 2 or 3 to the
• Tear bag 7 to create a passage. According to the invention, one does not or only partially follows the existing tear channel 2 or 3. Thus, according to the invention, a new channel is opened.
• a hollow cylindrical implant 100 can be used, which is stable enough in itself to serve as a Bugiernadel. In this case, no separate
• Bugiernadel 201 can be used. Particularly preferred is an implant 100 according to FIG. 4, at the hollow cylinder end of which an annular edge is provided which is designed as a cutting edge 104. In this case, with the cutting edge 104 of the implant 100, the required (s)
• the hollow implant 100 or solid implant 100 can be used directly. With a guide probe 200, a hollow cylindrical implant 100 can be more easily implanted in place.
• the implant 100 can be pushed from the eye 1 into the newly created openings in the direction of the nasal cavity 11.
• the implant 100 is severed or cut, as shown in FIG. 6 and FIG. 8 indicated. Both hollow implants 100 and solid implants 100 can be shortened to the desired length in this phase of the procedure.
• the end piece 107 can be removed through the nose.
• the implant 100 thus preferably ends approximately in the region of the lateral Siebbeins 14.
• a so-called guide probe 200 is used to better implant a hollow implant 100 can.
• the corresponding process is shown in FIG. 7 before removing the guide probe 200.
• the guide probe 200 is a pointed, thin elongate element in the form of a (Bugier) needle 201, which has a flexible thin projection 202 at the rear end, as shown in Fig. 5. With the pointed end (tip 203), the guide probe 200 z. B. in the region of the lower tear point 6 as possible introduced into the lower lacrimal duct 3.
• the operator looks for a new path in the direction of the tear-gas duct 7 and in the direction of one of the nasal concha 8 or 9.
• the tip 203 of the guide probe 200 With the tip 203 of the guide probe 200, the bones and / or cartilage structures of the nose can be easily penetrated. If that's because of thick and hard nasal wall and others
• Bone parts is not possible, can also be a microdrill through the
• Guide probe 200 can be inserted and used. Optionally, it can be observed from the inside of the nose with a lamp or an endoscope with a video camera and an optical instrument, whether the guide probe 200 passes in the desired area. after the
• Guide probe 200 pushed towards the final position. Once the final position of the implant 100 has been reached (as shown in FIG. 7), the guide probe 200 may be withdrawn toward the nose or towards the eye 1. When withdrawn, implant 100 should be held in place to prevent it from slipping, or optional barbs or nibs are used on implant 100 to hold implant 100 in place.
• a hollow guide probe 200 is used whose inner diameter is designed so that the implant 100 can be inserted into the interior of the hollow guide probe 200, before then the hollow guide probe 200 is removed. The hollow guide probe 200 can also be used to guide a microdrill to the correct position.
• the hollow guide probe 200 may also be used to insert an implant 100 formed of a cylindrical hollow body.
• FIG. 6 shows a similar situation as in FIG. 6, wherein the use of the guide probe 200 is shown here.
• the guide probe 200 was placed here in the correct position and it was either with a Bugiernadel or with the guide probe 200, the necessary openings produced. Then, the implant 100 was placed on the guide probe 200
• the delay can be from the
• FIG. 7 shows a situation in which the implant 100 has been pushed onto the guide probe 200 from the eye. This approach is preferred.
• a situation is shown in which the lower lacrimal duct 3 is blocked by a blockage 13.
• the implant 100 was used here so that it extends at least partially in the former tear duct 3 in the region between the lower tear point 6 and a first bend of the lower tear duct 3.
• the implant 100 then emerges from this tear duct 3 and extends in the direction of the tear-gas duct 7 and the ethmoid leg 14.
• the implant 100 here extends much more obliquely downwards than in FIG. 6.
• Fig. 9 a situation is shown in which the lower lacrimal duct 3 and the upper lacrimal duct 2 have each been replaced by an implant 100. Both implants 100 run here more or less parallel, but this is not necessarily so. The concrete situation depends on the
• FIGS. 10A to 10C Three steps for implanting a hollow implant 100 are shown in FIGS. 10A to 10C.
• a guide needle 204 is used, which has an elongated, needle-shaped base body 204.1, which opens at an extremal end in a ball head 205 or a tip.
• a flexible thread 206 e.g.
• a hollow implant 100 is shown in the appropriate size.
• the eye 1 and the nose are not shown in FIGS. 10A to 10C. Only in FIG. 1C is the position of one of the tear dots shown by a dashed line A.
• Fig. 10B It is shown that the implant 100 is pushed onto the guide needle 204 from the left.
• the guide needle 204 has been pushed before pushing the implant 100 through one of the tear ducts 2 or 3 in a prepared opening on the body. This body opening was, as already described, in the context of preparatory steps (eg.
• Tear spot is indicated by the dashed line A.
• the implant 100 is so far in the direction of the nose in the prepared body opening
• the guide needle 204 can be removed through the nose. Under certain circumstances, the guide needle 204 must be broken to remove into smaller pieces, which is easily possible from the nose. If the guide needle 204 is flexible in itself, the guide needle 204 can be removed without destruction.
• FIG. 11 shows a further embodiment of a hollow implant 100 with guide needle 207.
• the guide needle 207 here comprises a rod-shaped extension 209, which sits in the interior of the implant 100, and a tip 208 or ball. This embodiment facilitates the implanting of the hollow implant 100. After the implant 100 is seated in the correct position (analogous to FIG. 1C), the guide needle 207 can be removed.
• the implant 100 includes in all embodiments at the eye end an anti-rotation.
• Fig. 12 is one
• Embodiment shown in the funnel-shaped end portion 102 wing or fin-like lugs 109 are provided. After implantation in the body, this implant 100 is protected against twisting.
• FIG. 13 shows a similar embodiment, which was applied here to a hollow implant 100 without a funnel-shaped end region 102. Again, lugs 109 are provided as described. These embodiments can be applied to all other embodiments.
• the full implants 100 include in all
• Embodiments One or more barbs 112 and / or tabs 109 to achieve anchoring with body. Shown in Figures 16A-16C are exemplary barbs 112.
• FIG. 15A shows a highly schematic section through a newly created tear channel 110.
• the tear duct 110 is surrounded here by tissue, cartilage and / or bone 111. Inside the tear duct 110 sits the Voll-
• FIG. 15B shows a highly schematic section through the tear duct 110, after which the implant 100 has been completely resorbed. The fact that stabilizing structures form is shown in FIG. 15B indicated that the circumferential line of the tear duct 110 is shown in bold.
• the implant 100 may be designed as a resorbable or non-absorbable full implant.
• the implant 100 may be provided with a marking, e.g. in an x-ray, one
• Ultrasound image or an MRI (magnetic resonance imaging) is visible.
• a metallized label may be attached to the implant 100, or it may be a metal salt tag
• the position of the implant 100 can be precisely controlled on the body and corrected if necessary.
• the implant 100 is inserted so that it ends between 1 and 5 mm below the tear point 5 or 6, i. E. the implant 100 is not visible from the outside of the eye 1 in the inserted state.
• the implant 100 at the eye-side end 102 has a funnel-shaped
• the implant 100 will preferably be inserted into the prepared canal from the eye 1, and the funnel-shaped extension 108 will be in the implanted state
• the implant 100 is at least partially provided with a ceramic coating or a vitreous coating (eg, bioactive glass) to promote ingrowth in the bone of the nose.
• a ceramic coating or a vitreous coating eg, bioactive glass
• Bioactive glass preferably comprises a composition of silicon dioxide (SiO 2 ), calcium oxide (CaO) and P 2 O 5 (phosphorus pentoxide).
• a coating is alumina, calcium sulfate, fluoro-phosphorus-calcium hydroxide or the mentioned bioactive glass.
• a hydroxyapatite coating of the implant 100 is at least in the front region 106, as in Fig. 2A
• Hydroxiapatite is a calcium phosphate. Since in the implanted state only the front region 106 extends through bone, it is sufficient if approximately the foremost 10 to 50% of the total length L of the implant 100 are provided with such a coating. This applies to implants 100 that remain in the body. Inside, the lateral surface 105 of the implant 100 is preferably in all embodiments, dense and non-porous, so as not to add or block the channel to flow through the tears and to the
• This coating or this coating, for example, can be produced by sputtering or vapor deposition.
• the coating is designed so that a solid chemical bond between bone and the implant 100 occurs over time.
• the hollow implant 100 is inside with a
• Nano-coating coated to prevent the addition of the implant 100 with foreign bodies and to improve the flow through the tear fluid preferably has a strongly hydrophobic effect, so that the tear fluid beads better.
• a nano-coating comprising a silicone portion (e.g., in the form of silicone nanofilaments) is used. In all embodiments which are designed to be absorbable, it is not necessary to place importance on permanent ingrowth.
• Embodiments and a guide probe 200 has. Either it is a separate guide probe 200, on which the hollow implant 100 can be pushed, or it is a guide probe 200, which, as shown in Fig. 14, is connected to the solid implant 100. If it is about the insertion of a hollow implant 100, the outer diameter of the guide probe 200 is about 1 to 10% smaller than the inner diameter of the hollow implant 100.
• the insertion of the implant 100 according to the invention can also in the case of the tumor a solution because of the intrinsic stability of the
• Implant 100 also includes the artificially created tear ducts
• Hollow implants 100 are particularly suitable in such cases.
• the implant 100 can be removed as needed after a few months, when the surrounding structures have solidified. In most cases, however, the implant 100 remains permanently in the body, i.
• the implant 100 is designed specifically for permanent retention in the body.
• the implants 100 are designed as endoprostheses, i. E. they are for
• the implant 100 may also be designed to be resorbable in all embodiments, wherein the resorbability is predetermined so that the implant 100 decomposes within 6 months to 2 years after insertion in the body.
• a hollow implant 100 should ever be clogged, it can be easily reopened by inserting a thin needle.
• An advantage of the invention is the short operating time, which is only a few minutes.
• the complication rate is very low.
• the procedure can even be performed on an outpatient basis with general anesthesia. Reclosing, which may occur after removal of a ring intubation in some cases, does not occur in the practice of the present invention. LIST OF REFERENCE NUMBERS
• Eye / eyeball (Bulbus ocoli) 1 upper lacrimal tube (canaliculus 2 lacrimalis superioris)
• Tear bag (fundus sacci lacrimalis) 4 upper lacrimal punctum (punctum 5 lacrimal superius)
• Nasopharyngeal duct ductus naso 7 lacrimalis
• Device 100 nasal end 101 eye-side end 102

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Dermatology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Inorganic Chemistry (AREA)
• Ophthalmology & Optometry (AREA)
• Engineering & Computer Science (AREA)
• Plastic & Reconstructive Surgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Surgery (AREA)
• Vascular Medicine (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Prostheses (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (2)

Family

ID=48613651

Family Applications (1)

Country Status (2)

Family Cites Families (8)

• 2013
  • 2013-06-14 WO PCT/EP2013/062410 patent/WO2014001105A2/fr not_active Ceased
  • 2013-06-14 EP EP13728421.2A patent/EP2863841A2/fr not_active Withdrawn

Also Published As

Similar Documents

Legal Events